Biosimilars: Past, Present and Future

The first webinar of the year is on Biosimilars.
With the regulatory pathway for creating biosimilars getting close to legislative approval in the US, there has been increasing excitement in the biotech industry. Biosimilars are projected to be multi-billion dollar industry which unlike the generic drugs will cost a lot more to develop and make considerably higher revenues. What will the new pathway look like, what are the fine prints of the process, is it really going to be as profitable as projected, how does it protect the biotech and the generic industry, who finally wins in the process – patients or industry? Our first webinar this year will discuss these burning questions and more. There are several diverse opinions, some realities and many still to-be-determined factors that everyone thinking about biosimilars should know about. FDA’s perspective on biosimilars, the basics of the process, the potential issues and possible resolutions will be discussed.